US 11,719,694 B2
Biomarkers in autoimmune liver disease
Abdolamir Landi, Edmonton (CA); Michael Houghton, Danville, CA (US); D. Lorne Tyrrell, Edmonton (CA); Ferrucio Bonino, Pisa (IT); Maurizia Rossana Brunetto, Pisa (IT); Aldo Montano-Loza, Edmonton (CA); and Ana Clementin, Edmonton (CA)
Assigned to The Governors of the University of Alberta, Edmonton (CA)
Appl. No. 16/648,800
Filed by THE GOVERNORS OF THE UNIVERISTY OF ALBERTA, Edmonton (CA)
PCT Filed Oct. 10, 2018, PCT No. PCT/US2018/055280
§ 371(c)(1), (2) Date Mar. 19, 2020,
PCT Pub. No. WO2019/075109, PCT Pub. Date Apr. 18, 2019.
Claims priority of provisional application 62/571,034, filed on Oct. 11, 2017.
Prior Publication US 2020/0217844 A1, Jul. 9, 2020
Int. Cl. G01N 33/564 (2006.01); A61P 1/16 (2006.01); G01N 33/68 (2006.01); A61K 31/192 (2006.01); A61K 31/216 (2006.01); A61K 31/575 (2006.01)
CPC G01N 33/564 (2013.01) [A61K 31/192 (2013.01); A61K 31/216 (2013.01); A61K 31/575 (2013.01); A61P 1/16 (2018.01); G01N 33/6863 (2013.01); G01N 2333/521 (2013.01); G01N 2800/08 (2013.01); G01N 2800/085 (2013.01); G01N 2800/24 (2013.01); G01N 2800/52 (2013.01)] 13 Claims
OG exemplary drawing
 
1. A method for treating a subject diagnosed with an autoimmune hepatitis (AIH), the method comprising:
administering to a subject an effective amount of:
an immunosuppressive agent,
wherein the subject is identified as in need for treatment for the AIH based on having, in a body fluid sample, a level of CX3CL1 higher than a threshold level of CX3CL1.